Gradient Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Gradient Health provides a medical imaging data platform giving AI researchers and healthcare companies access to de-identified radiology datasets for model training and validation.
About
Gradient Health is a healthcare data company founded in 2019 that operates a platform providing access to de-identified medical imaging data for AI development, research, and regulatory validation. The company partners with health systems and imaging centers to source, de-identify, and structure radiology datasets including X-rays, CT scans, MRI studies, and pathology images that AI developers need to train and validate clinical algorithms. Obtaining sufficient high-quality labeled medical imaging data has been one of the primary bottlenecks for AI medical imaging companies, and Gradient Health addresses this by creating a market for compliant data access. The company uses advanced de-identification techniques that go beyond HIPAA minimum requirements to ensure patient privacy while preserving the clinical detail that makes datasets useful for AI training. Gradient serves medical imaging AI companies, pharmaceutical companies conducting imaging biomarker research, and academic medical centers building AI models. The company has built relationships with health systems across the US and has assembled imaging datasets spanning millions of studies across diverse patient populations and imaging equipment types.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.